{"transactions":[{"id":1735102,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2023-11-20T17:05:15.000Z","date":"2023-11-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation (\"Issuer\"), Zevra Therapeutics, Inc., a Delaware corporation (\"Zevra\"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra (\"Merger Sub\"), effective November 17, 2023 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-020441","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000089924323020441/doc4.xml","form_type":"4"}},{"id":1950647,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T16:41:45.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option, which is made as part of the issuer's 2023 annual compensation cycle, vests and becomes exercisable over four years as follows: 25% of the shares vest on March 14, 2024, and the remaining 75% of the shares vest quarterly over the remaining three years."}],"balance_after":30000,"derivative":{"exercise_price":1.67,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-019327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919123019327/doc4.xml","form_type":"4"}},{"id":2250057,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-01T20:11:53.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of May 31, 2023 or the date immediately prior to the Issuer's next annual meeting of stockholders."}],"balance_after":4400,"derivative":{"exercise_price":6.9,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0001209191-22-033137","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919122033137/doc4.xml","form_type":"4"}},{"id":2432769,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-19T16:24:03.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over four years as follows: 25% of the shares vest on January 14, 2023, and the remaining 75% of the shares vest quarterly over the remaining three years."}],"balance_after":25000,"derivative":{"exercise_price":2.21,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-003720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919122003720/doc4.xml","form_type":"4"}},{"id":2715119,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T20:18:47.000Z","date":"2021-05-11","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of May 11, 2022 or the date immediately prior to the Issuer's next annual meeting of stockholders."}],"balance_after":3750,"derivative":{"exercise_price":9.9,"expiration_date":"2031-05-11","underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-21-032331","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919121032331/doc4.xml","form_type":"4"}},{"id":2903006,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-20T16:15:50.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over four years as follows: 25% of the shares vest on January 15, 2022, and the remaining 75% of the shares vest quarterly over the remaining three years."}],"balance_after":60000,"derivative":{"exercise_price":3.85,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-21-004279","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919121004279/doc4.xml","form_type":"4"}},{"id":3075048,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Common Stock","published_at":"2020-07-28T09:01:07.000Z","date":"2020-07-24","kind":"purchase","acquired":true,"shares":14285,"price":3.5,"value":49997.5,"ownership":{"direct":true},"balance_after":14285,"source":{"system":"sec-edgar","filing":"0001209191-20-043803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919120043803/doc4.xml","form_type":"4"}},{"id":3149547,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-14T20:04:43.000Z","date":"2020-05-12","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of May 12, 2021 or the date immediately prior to the Issuer's next annual meeting of stockholders."}],"balance_after":22000,"derivative":{"exercise_price":0.43,"expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-20-029145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919120029145/doc4.xml","form_type":"4"}},{"id":3408299,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-09-23T19:38:23.000Z","date":"2019-09-18","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as follows: 50% on 01/01/2021 and 50% on 01/01/2022."}],"balance_after":40000,"derivative":{"exercise_price":3.42,"expiration_date":"2029-09-18","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-050506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919119050506/doc4.xml","form_type":"4"}},{"id":3526544,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-15T20:43:28.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest 100% on the earlier of May 14, 2020 or the date immediately prior to the Issuer's next annual meeting of stockholders."}],"balance_after":7000,"derivative":{"exercise_price":4.02,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-19-030043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919119030043/doc4.xml","form_type":"4"}},{"id":3675172,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-02-05T13:57:11.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over four years as follows: 25% of the shares vest on February 1, 2020, and 1/16th of the shares vest each quarter thereafter for the remaining three years."}],"balance_after":27000,"derivative":{"exercise_price":24.46,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-19-007243","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919119007243/doc4.xml","form_type":"4"}},{"id":3810078,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-09-21T20:44:57.000Z","date":"2018-09-20","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in monthly installments over one year commencing one month from September 20 2018."}],"balance_after":12000,"derivative":{"exercise_price":2.56,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-051904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919118051904/doc4.xml","form_type":"4"}},{"id":3958772,"issuer":{"id":108116,"kind":"organization","name":"Acer Therapeutics Inc.","symbol":"ACER"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer and Secy"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-04-23T16:32:30.000Z","date":"2018-04-20","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over four years as follows: 25% of the shares vest on April 20, 2019, and the remaining 75% vesting quarterly over the remaining three years."}],"balance_after":60000,"derivative":{"exercise_price":18.53,"expiration_date":"2028-04-20","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-18-025840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1069308/000120919118025840/doc4.xml","form_type":"4"}},{"id":4212010,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-12T19:09:12.000Z","date":"2017-08-01","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amended Form 4 is filed to correct the exercise price to reflect that the grant was effective as of the issuer's first open trading window after approval of the grant.  All other terms remain the same."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in monthly installments over 36 months commencing one month from August 1, 2017."}],"balance_after":16400,"derivative":{"exercise_price":2.89,"expiration_date":"2027-08-01","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-17-052393","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919117052393/doc4a.xml","form_type":"4/A","original_submission_date":"2017-08-03"}},{"id":4244371,"issuer":{"id":5072,"kind":"organization","name":"ACHIEVE LIFE SCIENCES, INC.","symbol":"ACHV"},"owners":[{"id":108120,"kind":"person","name":"Joseph Donald","position":1,"cik":"0001319460","reported_name":"Joseph Donald","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-08-04T00:49:38.000Z","date":"2017-08-01","kind":"grant","acquired":true,"shares":16400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in monthly installments over 36 months commencing one month from August 1, 2017."}],"balance_after":16400,"derivative":{"exercise_price":4.57,"expiration_date":"2027-08-01","underlying":"Common Stock","underlying_shares":16400},"source":{"system":"sec-edgar","filing":"0001209191-17-047584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/949858/000120919117047584/doc4.xml","form_type":"4"}}]}